Skip to main content
RPRX logo

Royalty Pharma plc

RPRXNASDAQHealthcareBiotechnology

$60.96Today:- (-)1Y +61.09%

As of Oct 16, 2026 close

Market cap
$33.21B
P/E (TTM)
40.75
Forward P/E
51.12
Dividend yield
1.55%
52-week range
$35.79$64.38
Volume (live)
-
Avg. volume (3M)
3.27M

Royalty Pharma (RPRX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Royalty Pharma generated $2.49B of operating cash flow. Free cash flow was $2.49B, down 10.1% from $2.77B a year earlier, or 104.7% of revenue. It returned $1.61B to shareholders through $378.25M in dividends and $1.23B in share buybacks.

Royalty Pharma Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Royalty Pharma plc (RPRX) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income1.321.331.700.040.621.702.461.521.34
Depreciation & Amortization0.000.000.000.010.020.020.020.030.03
Stock Based Compensation0.290.000.000.000.000.010.000.000.00
Change in Working Capital3.343.043.212.542.300.08-0.02-1.56-1.48
Change in Accounts Receivable3.352.983.202.512.300.000.160.11-0.08
Change in Accounts Payable-0.010.000.010.000.000.000.010.000.00
Change in Other Working Capital2.482.782.992.142.020.08-0.19-1.68-1.39
Other Operating Activities-2.47-1.60-1.92-2.08-1.480.23-0.791.631.52
Net Cash from Operating Activities2.492.772.992.142.022.031.671.621.42
Investing Activities
Acquisitions-0.07-0.01-0.01-0.01-0.03-0.04-0.03-0.020.00
Purchases of Investments-2.20-2.82-2.14-2.57-3.65-3.94-2.75-0.42-2.30
Sales/Maturities of Investments0.570.120.031.551.781.200.880.750.60
Other Investing Activities0.100.030.040.000.000.02-0.250.000.12
Net Cash from Investing Activities-1.61-2.68-2.07-1.03-1.87-2.76-2.150.30-1.59
Financing Activities
Debt Repayment-1.001.47-1.000.001.270.68-0.29-0.290.91
Common Stock Issued0.000.000.000.000.001.910.000.000.00
Common Stock Repurchased-1.23-0.23-0.300.000.000.000.000.000.00
Dividends Paid-0.38-0.38-0.36-0.33-0.29-0.40-0.74-0.81-0.74
Other Financing Activities-0.53-0.50-0.49-0.61-0.60-0.70-0.15-0.27-0.30
Net Cash from Financing Activities-1.190.36-2.15-0.940.391.49-1.19-1.38-0.12
Summary
Net Change in Cash-0.310.45-1.230.170.530.76-1.680.54-0.29
Cash at Beginning of Period0.930.481.711.541.010.251.921.381.67
Cash at End of Period0.620.930.481.711.541.010.251.921.38
Free Cash Flow2.492.772.992.142.022.031.671.621.42
Supplemental Disclosures
Interest Paid0.280.160.170.170.13----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Royalty Pharma Cash Flow

What is Royalty Pharma's free cash flow?

Royalty Pharma generated free cash flow of $2.49B in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 10.1% from $2.77B a year earlier. Free cash flow equaled 104.7% of revenue.

Does Royalty Pharma pay dividends or buy back shares?

Yes. In fiscal 2025 Royalty Pharma returned $378.25M in dividends and $1.23B in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition